Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program
© The Author(s), 2022..
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal-epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials.
Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021.
Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77 years (range, 48-91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47-69), whereas it was 68% (95% CI, 50-82) in treatment-naïve and 50% (95% CI, 35-65) in pretreated patients. The median progression-free survival was 9.5 months (95% CI, 4.7-14.3), whereas it was 10.6 months (95% CI, 5.5-15.7) in first-line and 9.1 months (95% CI, 3.1-15.1) in pretreated patients. After a median follow-up of 11.0 months, the median overall survival was 18.2 months (95% CI, 13.2-23.1). In patients with measurable brain metastases (n = 11), the intracranial ORR was 46% (95% CI, 17-77). Capmatinib showed a manageable safety profile. Grade ⩾ 3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%).
Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 14(2022) vom: 24., Seite 17588359221103206 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Illini, Oliver [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Capmatinib |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17588359221103206 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342420984 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342420984 | ||
| 003 | DE-627 | ||
| 005 | 20231226014057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17588359221103206 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342420984 | ||
| 035 | |a (NLM)35720834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Illini, Oliver |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) |b a retrospective analysis from an early access program |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2022. | ||
| 520 | |a Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal-epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials | ||
| 520 | |a Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021 | ||
| 520 | |a Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77 years (range, 48-91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47-69), whereas it was 68% (95% CI, 50-82) in treatment-naïve and 50% (95% CI, 35-65) in pretreated patients. The median progression-free survival was 9.5 months (95% CI, 4.7-14.3), whereas it was 10.6 months (95% CI, 5.5-15.7) in first-line and 9.1 months (95% CI, 3.1-15.1) in pretreated patients. After a median follow-up of 11.0 months, the median overall survival was 18.2 months (95% CI, 13.2-23.1). In patients with measurable brain metastases (n = 11), the intracranial ORR was 46% (95% CI, 17-77). Capmatinib showed a manageable safety profile. Grade ⩾ 3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%) | ||
| 520 | |a Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MET exon 14 skipping mutation | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a capmatinib | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Fabikan, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Swalduz, Aurélie |e verfasserin |4 aut | |
| 700 | 1 | |a Vikström, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Krenbek, Dagmar |e verfasserin |4 aut | |
| 700 | 1 | |a Schumacher, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Dudnik, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Studnicka, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Öhman, Ronny |e verfasserin |4 aut | |
| 700 | 1 | |a Wurm, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Wannesson, Luciano |e verfasserin |4 aut | |
| 700 | 1 | |a Peled, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Kian, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Bar, Jair |e verfasserin |4 aut | |
| 700 | 1 | |a Daher, Sameh |e verfasserin |4 aut | |
| 700 | 1 | |a Addeo, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Rotem, Ofer |e verfasserin |4 aut | |
| 700 | 1 | |a Pall, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Zer, Alona |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Akram |e verfasserin |4 aut | |
| 700 | 1 | |a Cufer, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Sorotsky, Hadas Gantz |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemi, Sayed M S |e verfasserin |4 aut | |
| 700 | 1 | |a Mohorcic, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Stoff, Ronen |e verfasserin |4 aut | |
| 700 | 1 | |a Rovitsky, Yulia |e verfasserin |4 aut | |
| 700 | 1 | |a Keren-Rosenberg, Shoshana |e verfasserin |4 aut | |
| 700 | 1 | |a Winder, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Weinlinger, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Valipour, Arschang |e verfasserin |4 aut | |
| 700 | 1 | |a Hochmair, Maximilian J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 14(2022) vom: 24., Seite 17588359221103206 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g day:24 |g pages:17588359221103206 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17588359221103206 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |b 24 |h 17588359221103206 | ||